Geron Corporation (0IV3.L)
USD 3.93
(-1.38%)
USD 3.93
(-1.38%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 394.07 Million USD | 106.78% |
| 2022 | 190.57 Million USD | -15.69% |
| 2021 | 226.03 Million USD | -16.51% |
| 2020 | 270.72 Million USD | 63.57% |
| 2019 | 165.51 Million USD | -10.67% |
| 2018 | 185.28 Million USD | 67.96% |
| 2017 | 110.31 Million USD | -15.31% |
| 2016 | 130.24 Million USD | -12.44% |
| 2015 | 148.76 Million USD | -13.77% |
| 2014 | 172.51 Million USD | 156.16% |
| 2013 | 67.34 Million USD | -32.52% |
| 2012 | 99.8 Million USD | -37.64% |
| 2011 | 160.04 Million USD | -31.48% |
| 2010 | 233.58 Million USD | 29.49% |
| 2009 | 180.38 Million USD | 2.36% |
| 2008 | 176.21 Million USD | -19.5% |
| 2007 | 218.89 Million USD | -0.86% |
| 2006 | 220.8 Million USD | 9.72% |
| 2005 | 201.24 Million USD | 52.6% |
| 2004 | 131.87 Million USD | 11.65% |
| 2003 | 118.11 Million USD | 94.69% |
| 2002 | 60.66 Million USD | -36.95% |
| 2001 | 96.23 Million USD | -15.61% |
| 2000 | 114.03 Million USD | 79.01% |
| 1999 | 63.7 Million USD | 43.15% |
| 1998 | 44.5 Million USD | 70.5% |
| 1997 | 26.1 Million USD | -9.38% |
| 1996 | 28.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 482.07 Million USD | 22.33% |
| 2024 Q2 | 449.39 Million USD | -6.78% |
| 2023 Q1 | 424.87 Million USD | 122.94% |
| 2023 Q4 | 394.07 Million USD | -4.59% |
| 2023 Q3 | 413.01 Million USD | -0.55% |
| 2023 FY | 394.07 Million USD | 106.78% |
| 2023 Q2 | 415.29 Million USD | -2.26% |
| 2022 FY | 190.57 Million USD | -15.69% |
| 2022 Q4 | 190.57 Million USD | -18.07% |
| 2022 Q1 | 198.42 Million USD | -12.22% |
| 2022 Q2 | 238.16 Million USD | 20.03% |
| 2022 Q3 | 232.6 Million USD | -2.33% |
| 2021 Q4 | 226.03 Million USD | -1.34% |
| 2021 FY | 226.03 Million USD | -16.51% |
| 2021 Q1 | 258.6 Million USD | -4.48% |
| 2021 Q2 | 252.17 Million USD | -2.49% |
| 2021 Q3 | 229.09 Million USD | -9.15% |
| 2020 FY | 270.72 Million USD | 63.57% |
| 2020 Q4 | 270.72 Million USD | -5.27% |
| 2020 Q1 | 142.88 Million USD | -13.67% |
| 2020 Q2 | 274.81 Million USD | 92.33% |
| 2020 Q3 | 285.79 Million USD | 4.0% |
| 2019 Q4 | 165.51 Million USD | 0.77% |
| 2019 FY | 165.51 Million USD | -10.67% |
| 2019 Q1 | 175.66 Million USD | -5.19% |
| 2019 Q2 | 166.22 Million USD | -5.37% |
| 2019 Q3 | 164.25 Million USD | -1.19% |
| 2018 Q4 | 185.28 Million USD | -1.41% |
| 2018 FY | 185.28 Million USD | 67.96% |
| 2018 Q3 | 187.93 Million USD | 2.55% |
| 2018 Q2 | 183.26 Million USD | 73.69% |
| 2018 Q1 | 105.51 Million USD | -4.35% |
| 2017 Q3 | 114.24 Million USD | -8.08% |
| 2017 Q4 | 110.31 Million USD | -3.44% |
| 2017 FY | 110.31 Million USD | -15.31% |
| 2017 Q1 | 128.84 Million USD | -1.08% |
| 2017 Q2 | 124.28 Million USD | -3.54% |
| 2016 Q2 | 137.41 Million USD | -4.0% |
| 2016 Q4 | 130.24 Million USD | -4.39% |
| 2016 Q1 | 143.14 Million USD | -3.78% |
| 2016 Q3 | 136.23 Million USD | -0.86% |
| 2016 FY | 130.24 Million USD | -12.44% |
| 2015 Q1 | 165.8 Million USD | -3.89% |
| 2015 Q4 | 148.76 Million USD | -3.41% |
| 2015 FY | 148.76 Million USD | -13.77% |
| 2015 Q3 | 154.01 Million USD | -3.18% |
| 2015 Q2 | 159.08 Million USD | -4.06% |
| 2014 Q1 | 155.4 Million USD | 130.77% |
| 2014 FY | 172.51 Million USD | 156.16% |
| 2014 Q2 | 149.33 Million USD | -3.91% |
| 2014 Q4 | 172.51 Million USD | 19.59% |
| 2014 Q3 | 144.24 Million USD | -3.41% |
| 2013 Q4 | 67.34 Million USD | -1.99% |
| 2013 Q1 | 82.85 Million USD | -16.98% |
| 2013 FY | 67.34 Million USD | -32.52% |
| 2013 Q2 | 73.41 Million USD | -11.4% |
| 2013 Q3 | 68.71 Million USD | -6.4% |
| 2012 FY | 99.8 Million USD | -37.64% |
| 2012 Q4 | 99.8 Million USD | -10.11% |
| 2012 Q3 | 111.02 Million USD | -12.02% |
| 2012 Q2 | 126.19 Million USD | -10.62% |
| 2012 Q1 | 141.18 Million USD | -11.78% |
| 2011 FY | 160.04 Million USD | -31.48% |
| 2011 Q1 | 217.02 Million USD | -7.09% |
| 2011 Q2 | 200.33 Million USD | -7.69% |
| 2011 Q3 | 188.4 Million USD | -5.95% |
| 2011 Q4 | 160.04 Million USD | -15.05% |
| 2010 Q1 | 180.72 Million USD | 0.19% |
| 2010 FY | 233.58 Million USD | 29.49% |
| 2010 Q4 | 233.58 Million USD | 43.93% |
| 2010 Q3 | 162.29 Million USD | -5.17% |
| 2010 Q2 | 171.13 Million USD | -5.31% |
| 2009 Q2 | 199.97 Million USD | -5.46% |
| 2009 FY | 180.38 Million USD | 2.36% |
| 2009 Q4 | 180.38 Million USD | -6.5% |
| 2009 Q3 | 192.92 Million USD | -3.53% |
| 2009 Q1 | 211.53 Million USD | 20.04% |
| 2008 Q4 | 176.21 Million USD | -6.2% |
| 2008 FY | 176.21 Million USD | -19.5% |
| 2008 Q1 | 210.61 Million USD | -3.78% |
| 2008 Q2 | 200.6 Million USD | -4.75% |
| 2008 Q3 | 187.85 Million USD | -6.36% |
| 2007 FY | 218.89 Million USD | -0.86% |
| 2007 Q4 | 218.89 Million USD | 0.59% |
| 2007 Q3 | 217.6 Million USD | -4.66% |
| 2007 Q2 | 228.23 Million USD | -0.33% |
| 2007 Q1 | 228.98 Million USD | 3.71% |
| 2006 Q4 | 220.8 Million USD | 21.29% |
| 2006 Q3 | 182.04 Million USD | -4.48% |
| 2006 FY | 220.8 Million USD | 9.72% |
| 2006 Q1 | 194.31 Million USD | -3.44% |
| 2006 Q2 | 190.58 Million USD | -1.92% |
| 2005 FY | 201.24 Million USD | 52.6% |
| 2005 Q4 | 201.24 Million USD | -4.06% |
| 2005 Q3 | 209.75 Million USD | 52.06% |
| 2005 Q2 | 137.93 Million USD | 1.52% |
| 2005 Q1 | 135.87 Million USD | 3.03% |
| 2004 Q1 | 114.67 Million USD | -2.91% |
| 2004 Q3 | 99.63 Million USD | -8.56% |
| 2004 FY | 131.87 Million USD | 11.65% |
| 2004 Q4 | 131.87 Million USD | 32.35% |
| 2004 Q2 | 108.96 Million USD | -4.98% |
| 2003 FY | 118.11 Million USD | 94.69% |
| 2003 Q1 | 52.51 Million USD | -13.45% |
| 2003 Q3 | 58.98 Million USD | -7.34% |
| 2003 Q2 | 63.66 Million USD | 21.23% |
| 2003 Q4 | 118.11 Million USD | 100.23% |
| 2002 FY | 60.66 Million USD | -36.95% |
| 2002 Q1 | 84.43 Million USD | -12.26% |
| 2002 Q4 | 60.66 Million USD | -11.45% |
| 2002 Q3 | 68.51 Million USD | -10.17% |
| 2002 Q2 | 76.26 Million USD | -9.67% |
| 2001 FY | 96.23 Million USD | -15.61% |
| 2001 Q2 | 103.27 Million USD | -4.16% |
| 2001 Q1 | 107.76 Million USD | -5.49% |
| 2001 Q3 | 96.81 Million USD | -6.26% |
| 2001 Q4 | 96.23 Million USD | -0.61% |
| 2000 FY | 114.03 Million USD | 79.01% |
| 2000 Q3 | 115.2 Million USD | -3.46% |
| 2000 Q2 | 119.33 Million USD | 21.14% |
| 2000 Q1 | 98.5 Million USD | 54.64% |
| 2000 Q4 | 114.03 Million USD | -1.02% |
| 1999 Q2 | 62.2 Million USD | 47.04% |
| 1999 Q1 | 42.3 Million USD | -4.94% |
| 1999 FY | 63.7 Million USD | 43.15% |
| 1999 Q4 | 63.7 Million USD | -6.6% |
| 1999 Q3 | 68.2 Million USD | 9.65% |
| 1998 Q1 | 41.9 Million USD | 60.54% |
| 1998 Q2 | 40.7 Million USD | -2.86% |
| 1998 Q4 | 44.5 Million USD | 16.8% |
| 1998 FY | 44.5 Million USD | 70.5% |
| 1998 Q3 | 38.1 Million USD | -6.39% |
| 1997 Q2 | 31 Million USD | 20.16% |
| 1997 Q1 | 25.8 Million USD | -10.42% |
| 1997 FY | 26.1 Million USD | -9.38% |
| 1997 Q4 | 26.1 Million USD | -7.77% |
| 1997 Q3 | 28.3 Million USD | -8.71% |
| 1996 Q3 | 32 Million USD | 71.12% |
| 1996 Q4 | 28.8 Million USD | -10.0% |
| 1996 Q1 | 18.1 Million USD | 0.0% |
| 1996 FY | 28.8 Million USD | 0.0% |
| 1996 Q2 | 18.7 Million USD | 3.31% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 21.051% |
| Dynavax Technologies Corporation | 997.09 Million USD | 60.478% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 72.031% |
| Perrigo Company plc | 10.8 Billion USD | 96.354% |
| Illumina, Inc. | 10.11 Billion USD | 96.103% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.601% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 49.5% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.514% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 98.523% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -77.108% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.809% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -499.903% |
| Waters Corporation | 4.62 Billion USD | 91.483% |
| Biogen Inc. | 26.84 Billion USD | 98.532% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -138.372% |
| Evolus, Inc. | 188.99 Million USD | -108.508% |
| Adicet Bio, Inc. | 207.29 Million USD | -90.104% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -213.146% |
| bluebird bio, Inc. | 619.16 Million USD | 36.353% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -91.489% |
| FibroGen, Inc. | 423.52 Million USD | 6.954% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 96.339% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1293.854% |
| Homology Medicines, Inc. | 47.05 Million USD | -737.444% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 89.71% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 49.34% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 67.125% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -6.943% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 69.709% |
| Zoetis Inc. | 14.28 Billion USD | 97.242% |
| Abeona Therapeutics Inc. | 64 Million USD | -515.725% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 88.256% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 94.24% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.266% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -604.349% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 86.821% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -138.107% |
| Verastem, Inc. | 149.71 Million USD | -163.212% |
| Nektar Therapeutics | 398.03 Million USD | 0.994% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 33.007% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -99.628% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 87.929% |
| OPKO Health, Inc. | 2.01 Billion USD | 80.411% |
| Exelixis, Inc. | 2.94 Billion USD | 86.607% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 87.88% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 36.594% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -155.254% |
| uniQure N.V. | 831.68 Million USD | 52.617% |
| Imunon, Inc. | 21.91 Million USD | -1697.95% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 62.442% |
| Insmed Incorporated | 1.32 Billion USD | 70.367% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 77.264% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 57.948% |
| TG Therapeutics, Inc. | 329.58 Million USD | -19.567% |
| Incyte Corporation | 6.78 Billion USD | 94.189% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 78.523% |